Form 4: Amicus Therapeutics Director Lynn Dorsey Bleil Reports Acquisition of Restricted Stock Units and Stock Options

Director Lynn Dorsey Bleil reports acquiring 11,847 restricted stock units and 42,467 stock options in Amicus Therapeutics.

Summary

• Lynn Dorsey Bleil, a director of Amicus Therapeutics, reported changes in beneficial ownership on June 7, 2024.
• On June 6, 2024, Bleil acquired 11,847 shares of common stock in the form of Restricted Stock Units (RSUs) at a price of $0.00.
• These RSUs will vest in full on the one-year anniversary of the grant date and are payable in common stock.
• One RSU is equivalent to one share of Amicus common stock.
• Bleil also acquired 42,467 stock options with an exercise price of $10.27 on June 6, 2024.
• These options will vest and become exercisable on the one-year anniversary of the grant date, June 6, 2025.
• Following these transactions, Bleil directly owns 93,527 shares of Amicus common stock and 42,467 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports standard insider transactions. The acquisition of shares and options can be seen as a positive sign, but it's a routine disclosure.

Positives

• The acquisition of RSUs and stock options by a director signals confidence in the company's future performance.

Future Outlook

The RSUs vest in one year and are payable in common stock, indicating a long-term incentive for the director.

Industry Context

Form 4 filings are standard disclosures for corporate insiders and provide transparency into their transactions, which can influence investor sentiment.

Comparison to Industry Standards

• Stock option grants and RSU grants are common forms of executive compensation in the biotechnology industry, aligning management interests with shareholder value.
• The vesting schedules are typical, with one-year vesting periods being a standard practice.

Stakeholder Impact

• The transactions could have a minor positive impact on shareholder confidence due to the director's increased stake in the company.

Key Dates